Aquestive Therapeutics Q3 net loss widens 7% to $16.5 million; revenue drops 41% to $7.56 million
AQST•Aquestive Therapeutics’ third-quarter 2026 net loss widened 7% year over year to $16.5 million, while revenue fell 41% to $7.56 million. The FDA accepted Anaphylm’s resubmission with a March 16, 2027 decision goal date, and full-year revenue guidance remained $46 million to $50 million.
1. Quarterly results and outlook
Aquestive Therapeutics reported a third-quarter 2026 net loss of $16.5 million, up 7% year over year, and revenue of $7.56 million, down 41%, primarily due to quarterly fluctuations in Suboxone product orders. The FDA accepted Anaphylm’s resubmission and set a March 16, 2027 decision goal date; commercial preparations continue for a potential launch. The company kept its 2026 revenue guidance at $46 million to $50 million.
